Matter Bio
Longevity therapeutics targeting genomic integrity and DNA damage.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | N/A | Grant | |
| Total Funding | 000k | ||
Related Content
Matter Bio is a biotechnology holding company founded in 2022 that focuses on extending healthy human lifespans by preserving genome integrity. The company operates on the principle that aging is fundamentally a process of information loss at the genomic level, caused by the continuous accumulation of DNA damage. To counter this, Matter Bio employs a multi-pronged strategy: reading and detecting genomic information loss, reversing integrated mutations, and removing cells too damaged for repair, such as cancerous or senescent cells.
The company was co-founded by CEO Chris Bradley and prominent scientists including George Church, a pioneer in genome sequencing; Jan Vijg, an expert in genome instability; and Claudia Gravekamp, an authority in bacterial therapeutics. Matter Bio operates with a hub-and-spoke business model, managing a portfolio of subsidiary companies, each targeting a specific stage of the genomic information loss continuum. This portfolio includes assets at various stages, from a revenue-generating single-molecule mutation sequencing service to a program entering Phase 1/2a clinical trials for solid cancer.
In May 2024, Matter Bio announced the closure of a $7 million seed funding round led by Lifespan Vision Ventures, with participation from quadraScope Ventures and others, including grant support from the NIH, NCI, and NIEHS. These funds are allocated to furthering research into the information theory of aging, filing an Investigational New Drug (IND) application, and initiating clinical trials. The firm's approach also involves large-scale research collaborations, analyzing data from tens of thousands of human and animal genomes to identify genetic keys to exceptional longevity.
Keywords: longevity, genome integrity, DNA repair, healthspan, aging, somatic mutations, gene editing, cancer therapeutics, cellular senescence, genomics, biotechnology, information theory of aging, preventative health, clinical trials, sequencing, genetic interventions, DNA damage, rejuvenation, molecular biology, life extension